Translocation Renal Cell Carcinoma
Showing 1 - 25 of >10,000
MiT Family Translocation Renal Cell Carcinomas (IMCOR)
Not yet recruiting
- Renal Carcinoma
- Data collection
-
Bordeaux, France
- +3 more
Jul 8, 2022
Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1, Papillary Renal Cell Carcinoma Type 2 Trial in Australia
Recruiting
- Renal Cell Carcinoma
- +5 more
-
Albury, New South Wales, Australia
- +10 more
Feb 14, 2022
Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1, Papillary Renal Cell Carcinoma Type 2 Trial in Australia
Active, not recruiting
- Renal Cell Carcinoma
- +5 more
-
Albury, New South Wales, Australia
- +18 more
Feb 14, 2022
Delving Into Participation Trends in Renal Cell Carcinoma
Not yet recruiting
- Renal Cell Carcinoma
-
San Francisco, CaliforniaPower Life Sciences
Oct 16, 2023
Renal Cell Carcinoma Trial in Beijing (68Ga-NY104 PET/CT)
Recruiting
- Renal Cell Carcinoma
- 68Ga-NY104 PET/CT
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Jun 5, 2023
Moesin Expression in Clear Cell Renal Cell Carcinoma
Completed
- Renal Cell Carcinoma
- Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma
- (no location specified)
Sep 20, 2023
Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-NY104 PET/CT)
Not yet recruiting
- Clear Cell Renal Cell Carcinoma
- 68Ga-NY104 PET/CT
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
May 18, 2023
Metastatic Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-NY104 PET/CT)
Not yet recruiting
- Metastatic Clear Cell Renal Cell Carcinoma
- 68Ga-NY104 PET/CT
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
May 18, 2023
Clear Cell Renal Cell Carcinoma Trial in Los Angeles (89Zr-DFO-girentuximab)
Available
- Clear Cell Renal Cell Carcinoma
- 89Zr-DFO-girentuximab
-
Los Angeles, CaliforniaUCLA
Oct 12, 2023
Clear Cell Renal Cell Carcinoma Trial in Beijing (68Ga-NY104 PET/CT)
Not yet recruiting
- Clear Cell Renal Cell Carcinoma
- 68Ga-NY104 PET/CT
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
May 28, 2023
Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody
Recruiting
- Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
- AK104(anti-PD-1/CTLA-4 bi-specific antibody ,intravenously),lenvatinib( targeted VEGFR 1-3、FGFR、PDGFRα, small molecule TKI,orally
-
Shanghai, Shanghai, ChinaShanghai Renji Hospital
Sep 12, 2023
Clear Cell Renal Cell Carcinoma, Suspected Recurrent Renal Clear Cell Carcinoma, Recurrent Renal Cell Cancer Trial
Not yet recruiting
- Clear Cell Renal Cell Carcinoma
- +2 more
- (no location specified)
May 14, 2023
Advanced Renal Cell Carcinoma Trial in Beijing (ST-1898 tablets)
Recruiting
- Advanced Renal Cell Carcinoma
- ST-1898 tablets
-
Beijing, Beijing, ChinaPeking University Cancer Hospital & Institute
Nov 6, 2023
Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer Trial in Boston (Implantable Microdevice (IMD))
Not yet recruiting
- Renal Cell Carcinoma
- +2 more
- Implantable Microdevice (IMD)
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 17, 2023
Renal Cell Carcinoma Trial in Birmingham (Pembrolizumab injection)
Not yet recruiting
- Renal Cell Carcinoma
- Pembrolizumab injection
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Aug 20, 2023
Renal Cell Carcinoma Trial in Tabriz (Sodium Pentaborate)
Not yet recruiting
- Renal Cell Carcinoma
- Sodium Pentaborate
-
Tabriz, East Azarbayejan, Iran, Islamic Republic ofImam Reza hospital and Clinic of Salamat
Mar 23, 2023
Papillary Renal Cell Carcinoma Trial (Pembrolizumab, Placebo)
Not yet recruiting
- Papillary Renal Cell Carcinoma
- Pembrolizumab
- Placebo
- (no location specified)
Nov 24, 2023
Metastatic Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Stage III Renal
Recruiting
- Metastatic Renal Cell Carcinoma
- +4 more
- Axitinib
- Nivolumab
-
Birmingham, Alabama
- +255 more
Aug 24, 2022
Renal Cell Carcinoma Trial in Guangzhou (Pucotenlimab Combined With Lenvatinib)
Not yet recruiting
- Renal Cell Carcinoma
- Pucotenlimab Combined With Lenvatinib
-
Guangzhou, Other (Non U.s.), ChinaSun Yat-sen University Cancer Center
Nov 10, 2023
Advanced Clear Cell Renal Carcinoma (Ccrcc), Papillary Renal Cell Carcinoma (Prcc) Trial run by the National Cancer Institute
Not yet recruiting
- Advanced Clear Cell Renal Carcinoma (Ccrcc)
- Papillary Renal Cell Carcinoma (Prcc)
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Sutureless Zero Ischemia Laparoscopic Tumor Enucleation for T1
Recruiting
- Carcinoma, Renal Cell
- Kidney Neoplasms
-
Yiwu, Zhejiang, ChinaThe Fourth Affiliated Hospital Zhejiang University School of Med
Mar 27, 2023